127 related articles for article (PubMed ID: 29022906)
1. Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.
Xu J; Zheng L; Chen J; Sun Y; Lin H; Jin RA; Tang M; Liang X; Cai X
Cell Death Dis; 2017 Oct; 8(10):e3095. PubMed ID: 29022906
[TBL] [Abstract][Full Text] [Related]
2. Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
Toledo M; Penna F; Busquets S; López-Soriano FJ; Argilés JM
PLoS One; 2014; 9(12):e113931. PubMed ID: 25436606
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2
Xie C; Gao X; Sun D; Zhang Y; Krausz KW; Qin X; Gonzalez FJ
Drug Metab Dispos; 2018 Apr; 46(4):336-345. PubMed ID: 29363499
[TBL] [Abstract][Full Text] [Related]
4. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Courtney KD; Infante JR; Lam ET; Figlin RA; Rini BI; Brugarolas J; Zojwalla NJ; Lowe AM; Wang K; Wallace EM; Josey JA; Choueiri TK
J Clin Oncol; 2018 Mar; 36(9):867-874. PubMed ID: 29257710
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
Liang Y; Chen J; Yu Q; Ji T; Zhang B; Xu J; Dai Y; Xie Y; Lin H; Liang X; Cai X
Cancer Med; 2017 Dec; 6(12):2787-2795. PubMed ID: 29030911
[TBL] [Abstract][Full Text] [Related]
6. Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis.
Xie C; Yagai T; Luo Y; Liang X; Chen T; Wang Q; Sun D; Zhao J; Ramakrishnan SK; Sun L; Jiang C; Xue X; Tian Y; Krausz KW; Patterson AD; Shah YM; Wu Y; Jiang C; Gonzalez FJ
Nat Med; 2017 Nov; 23(11):1298-1308. PubMed ID: 29035368
[TBL] [Abstract][Full Text] [Related]
7. A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor.
Dao DT; Anez-Bustillos L; Jabbouri SS; Pan A; Kishikawa H; Mitchell PD; Fell GL; Baker MA; Watnick RS; Chen H; Rogers MS; Bielenberg DR; Puder M
PLoS One; 2018; 13(12):e0208579. PubMed ID: 30566445
[TBL] [Abstract][Full Text] [Related]
8. Functions of human liver CD69
Kim JH; Han JW; Choi YJ; Rha MS; Koh JY; Kim KH; Kim CG; Lee YJ; Kim AR; Park J; Kim HK; Min BS; Seo SI; Kang M; Park HJ; Han DH; Kim SI; Kim MS; Lee JG; Lee DH; Kim W; Park JY; Park SH; Joo DJ; Shin EC
J Hepatol; 2020 Jun; 72(6):1170-1181. PubMed ID: 31987989
[TBL] [Abstract][Full Text] [Related]
9. Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control.
Cheng X; Prange-Barczynska M; Fielding JW; Zhang M; Burrell AL; Lima JD; Eckardt L; Argles I; Pugh CW; Buckler KJ; Robbins PA; Hodson EJ; Bruick RK; Collinson LM; Rastinejad F; Bishop T; Ratcliffe PJ
J Clin Invest; 2020 May; 130(5):2237-2251. PubMed ID: 31999648
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
Méndez-Blanco C; Fondevila F; García-Palomo A; González-Gallego J; Mauriz JL
Exp Mol Med; 2018 Oct; 50(10):1-9. PubMed ID: 30315182
[TBL] [Abstract][Full Text] [Related]
11. N
Xu J; Wan Z; Tang M; Lin Z; Jiang S; Ji L; Gorshkov K; Mao Q; Xia S; Cen D; Zheng J; Liang X; Cai X
Mol Cancer; 2020 Nov; 19(1):163. PubMed ID: 33222692
[TBL] [Abstract][Full Text] [Related]
12. HIF-2α is indispensable for regulatory T cell function.
Hsu TS; Lin YL; Wang YA; Mo ST; Chi PY; Lai AC; Pan HY; Chang YJ; Lai MZ
Nat Commun; 2020 Oct; 11(1):5005. PubMed ID: 33024109
[TBL] [Abstract][Full Text] [Related]
13. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
Wehn PM; Rizzi JP; Dixon DD; Grina JA; Schlachter ST; Wang B; Xu R; Yang H; Du X; Han G; Wang K; Cao Z; Cheng T; Czerwinski RM; Goggin BS; Huang H; Halfmann MM; Maddie MA; Morton EL; Olive SR; Tan H; Xie S; Wong T; Josey JA; Wallace EM
J Med Chem; 2018 Nov; 61(21):9691-9721. PubMed ID: 30289716
[TBL] [Abstract][Full Text] [Related]
14. Microbial Metabolite Signaling Is Required for Systemic Iron Homeostasis.
Das NK; Schwartz AJ; Barthel G; Inohara N; Liu Q; Sankar A; Hill DR; Ma X; Lamberg O; Schnizlein MK; Arqués JL; Spence JR; Nunez G; Patterson AD; Sun D; Young VB; Shah YM
Cell Metab; 2020 Jan; 31(1):115-130.e6. PubMed ID: 31708445
[TBL] [Abstract][Full Text] [Related]
15. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Courtney KD; Ma Y; Diaz de Leon A; Christie A; Xie Z; Woolford L; Singla N; Joyce A; Hill H; Madhuranthakam AJ; Yuan Q; Xi Y; Zhang Y; Chang J; Fatunde O; Arriaga Y; Frankel AE; Kalva S; Zhang S; McKenzie T; Reig Torras O; Figlin RA; Rini BI; McKay RM; Kapur P; Wang T; Pedrosa I; Brugarolas J
Clin Cancer Res; 2020 Feb; 26(4):793-803. PubMed ID: 31727677
[TBL] [Abstract][Full Text] [Related]
16. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor.
Renfrow JJ; Soike MH; West JL; Ramkissoon SH; Metheny-Barlow L; Mott RT; Kittel CA; D'Agostino RB; Tatter SB; Laxton AW; Frenkel MB; Hawkins GA; Herpai D; Sanders S; Sarkaria JN; Lesser GJ; Debinski W; Strowd RE
Sci Rep; 2020 Sep; 10(1):15195. PubMed ID: 32938997
[TBL] [Abstract][Full Text] [Related]
17. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.
Persson CU; von Stedingk K; Fredlund E; Bexell D; Påhlman S; Wigerup C; Mohlin S
Exp Cell Res; 2020 Mar; 388(2):111845. PubMed ID: 31945318
[TBL] [Abstract][Full Text] [Related]
18. Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload.
Schwartz AJ; Das NK; Ramakrishnan SK; Jain C; Jurkovic MT; Wu J; Nemeth E; Lakhal-Littleton S; Colacino JA; Shah YM
J Clin Invest; 2019 Jan; 129(1):336-348. PubMed ID: 30352047
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer.
Bao MH; Wong CC
Cells; 2021 Jul; 10(7):. PubMed ID: 34359884
[TBL] [Abstract][Full Text] [Related]
20. Development of synthetic lethality in cancer: molecular and cellular classification.
Li S; Topatana W; Juengpanich S; Cao J; Hu J; Zhang B; Ma D; Cai X; Chen M
Signal Transduct Target Ther; 2020 Oct; 5(1):241. PubMed ID: 33077733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
